Alterity Therapeutics Limited
PRNAF
$0.01
$0.00-44.55%
OTC PK
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | 4.27M | 3.87M | 3.49M | 2.96M | 2.46M |
| Total Revenue | 4.27M | 3.87M | 3.49M | 2.96M | 2.46M |
| Cost of Revenue | 105.30K | 93.60K | 82.60K | 100.80K | 119.30K |
| Gross Profit | 4.16M | 3.78M | 3.41M | 2.86M | 2.34M |
| SG&A Expenses | 4.73M | 4.13M | 3.56M | 3.76M | 3.97M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 144.80K | 100.40K | 56.70K | 47.40K | 38.30K |
| Total Operating Expenses | 15.63M | 14.26M | 12.99M | 14.46M | 15.99M |
| Operating Income | -11.36M | -10.39M | -9.50M | -11.50M | -13.53M |
| Income Before Tax | -9.37M | -8.57M | -7.85M | -10.42M | -13.02M |
| Income Tax Expenses | 83.40K | 63.20K | 43.10K | 36.50K | 30.40K |
| Earnings from Continuing Operations | -9.45 | -8.64 | -7.89 | -10.46 | -13.05 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.45M | -8.64M | -7.89M | -10.46M | -13.05M |
| EBIT | -11.36M | -10.39M | -9.50M | -11.50M | -13.53M |
| EBITDA | -11.35M | -10.37M | -9.48M | -11.48M | -13.51M |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 35.32B | 30.45B | 25.59B | 22.90B | 20.22B |
| Average Diluted Shares Outstanding | 35.32B | 30.45B | 25.59B | 22.90B | 20.22B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |